NASDAQ: IKNA
Ikena Oncology Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their IKNA stock forecasts and price targets.

Forecast return on equity

Is IKNA forecast to generate an efficient return?

Company
-65.7%
Industry
140.91%
Market
90.47%
IKNA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IKNA forecast to generate an efficient return on assets?

Company
-59.38%
Industry
32.45%
IKNA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IKNA earnings per share forecast

What is IKNA's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.58
Avg 2 year Forecast
-$0.62
Avg 3 year Forecast
-$0.97

IKNA revenue forecast

What is IKNA's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$23.0M
Avg 2 year Forecast
$58.0M
Avg 3 year Forecast
$94.0M

IKNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IKNA$1.35N/AN/A
MNOV$1.33$9.00+576.69%Strong Buy
ANRO$2.41$10.67+342.61%Buy
QNCX$1.43$7.67+436.15%Strong Buy
ABOS$1.07$7.50+600.93%Strong Buy

Ikena Oncology Stock Forecast FAQ

What is IKNA's earnings growth forecast for 2025-2027?

(NASDAQ: IKNA) Ikena Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Ikena Oncology's earnings in 2025 is -$41,707,000.On average, 2 Wall Street analysts forecast IKNA's earnings for 2025 to be -$27,989,704, with the lowest IKNA earnings forecast at -$28,472,285, and the highest IKNA earnings forecast at -$27,507,123. On average, 2 Wall Street analysts forecast IKNA's earnings for 2026 to be -$29,920,029, with the lowest IKNA earnings forecast at -$36,193,583, and the highest IKNA earnings forecast at -$23,646,474.

In 2027, IKNA is forecast to generate -$46,569,077 in earnings, with the lowest earnings forecast at -$70,456,842 and the highest earnings forecast at -$22,681,312.

If you're new to stock investing, here's how to buy Ikena Oncology stock.

What is IKNA's revenue growth forecast for 2028-2030?

(NASDAQ: IKNA) Ikena Oncology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Ikena Oncology's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast IKNA's revenue for 2028 to be $1,109,936,553, with the lowest IKNA revenue forecast at $1,109,936,553, and the highest IKNA revenue forecast at $1,109,936,553. On average, 1 Wall Street analysts forecast IKNA's revenue for 2029 to be $2,798,970,438, with the lowest IKNA revenue forecast at $2,798,970,438, and the highest IKNA revenue forecast at $2,798,970,438.

In 2030, IKNA is forecast to generate $4,536,262,434 in revenue, with the lowest revenue forecast at $4,536,262,434 and the highest revenue forecast at $4,536,262,434.

What is IKNA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: IKNA) forecast ROA is -59.38%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is IKNA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: IKNA) Ikena Oncology's current Earnings Per Share (EPS) is -$0.86. On average, analysts forecast that IKNA's EPS will be -$0.58 for 2025, with the lowest EPS forecast at -$0.59, and the highest EPS forecast at -$0.57. On average, analysts forecast that IKNA's EPS will be -$0.62 for 2026, with the lowest EPS forecast at -$0.75, and the highest EPS forecast at -$0.49. In 2027, IKNA's EPS is forecast to hit -$0.97 (min: -$1.46, max: -$0.47).

What is IKNA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: IKNA) forecast ROE is -65.7%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.